Friday, November 22, 2024 11/22/2024

Development of SupraGuard ETT, A Next Generation Composite Endotracheal Tube for the Prevention of Ventilator-Associated Pneumonia

Award Number: R43HL156363
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Project Summary Abstract The Centers for Disease Control and Prevention (CDC) reports that preventing ventilator associated pneumonia (VAP), as opposed to treating the acquired infection, is a critical and unmet need. To respond to this need, Iasis Molecular Sciences will leverage strong preliminary data obtained for proprietary antimicrobial compositions (composites). Excellent antimicrobial performance and material cytocompatibility could be beneficial in the creation of a next generation endotracheal tube that could substantively reduce VAP. SupraGuardTM ETT is an advanced device wholly constructed from an antimicrobial composite designed to kill microorganisms known to cause VAP. The compositions are effective against organisms intraluminally or those located in subglottic fluids that have pooled above the cuff while maintaining excellent mechanical characteristics. The proposed research will address ETT composite formulation, composite processing, microbial inactivation, composite biocompatibility and stability, and ETT cuff viability. The major specific aims of the proposed research include: 1.) Finalizing SupraGuardTM Next Generation Antimicrobial Endotracheal Tube & Cuff Materials Development, 2.) Measure the Antibacterial & Antifungal Effectiveness of the SupraGuardTM Composites. 3.) Evaluate the In Vitro & In Vivo Biocompatibility of SupraGuardTM Composites. There is significant commercial potential for our product, as the antimicrobial-coated ETT component of the ETT market was valued at $1.84B in 2018 and whereby the majority of antimicrobial ETTs are silver-coated ETTs. However, there are no products today that possess effective antimicrobial ETT cuffs that can effectively kill pathogens.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	IASIS MOLECULAR SCIENCES INC.	120 N PINE ST	SPOKANE	WA	99202	SPOKANE	USA	Lung Diseases Research	000	1	4/11/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	IASIS MOLECULAR SCIENCES INC.	120 N PINE ST	SPOKANE	WA	99202	SPOKANE	USA	Lung Diseases Research	000	1	9/2/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $225,135 )
2021	2021	IASIS MOLECULAR SCIENCES INC.	120 N PINE ST	SPOKANE	WA	99202	SPOKANE	USA	Lung Diseases Research	000	1	9/9/2021	NEW	$225,135
														Subtotal = $225,135

Grand Total All Awards = $225,135

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of SupraGuard ETT, A Next Generation Composite Endotracheal Tube for the Prevention of Ventilator-Associated Pneumonia

Award Number: R43HL156363

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer